OSLO: Lytix Biopharma, a Norwegian immune-oncology company, announced the appointment of Stephen Worsley as Chief Business Officer (CBO). Stephen Worsley is a pharmaceutical executive with over 25 years of experience in business development leadership in roles of increasing impact and in executing high-valuation strategic deals in the biopharmaceutical and drug discovery/development market. As a business…